 7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response 70 CR rate 5 CRs achieved across all dose levels after a single cycle 3 weekly doses of NKX019 monotherapy; 3 partial responses deepened to CR with additional cycles Patients with CR observed ... The post Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma appeared fi... 